Can chemoprevention reduce the risk of prostate cancer?

Clinical Chemistry

Volumn 56, Issue 8, 2010, Pages 1214-1215

  Diamandis, Eleftherios P ^a,b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

CANCER PREVENTION; CANCER RISK; ERECTILE DYSFUNCTION; GLEASON SCORE; GYNECOMASTIA; HUMAN; LIBIDO DISORDER; LIFE EVENT; MALE; PROSTATE BIOPSY; PROSTATE CANCER; SHORT SURVEY; SIDE EFFECT; SPERMATOZOON COUNT;

ANTICARCINOGENIC AGENTS; AZASTEROIDS; FINASTERIDE; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK;

EID: 77955253657     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.147918     Document Type: Short Survey

References (5)

1. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192-202.
2. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
3. Murtola TJ, Tammela TL, Määttänen L, Ala-Opas M, Stenman UH, Auvinen A. Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial. Br J Cancer 2009;101:843-8.
4. Kramer BS, Hagerty KL, Justman S, Somerfield MR, Albertsen PC, Blot WJ, et al. Use of 5α-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Urol 2009;181:1642-57.
5. Walsh PC. Chemoprevention of prostate cancer. N Engl J Med 2010;362:1237-8.